Brief: Prothena Announces Bristol Myers Squibb Opt-In For Exclusive Global License For Prx019

Prothena

28/05/2024 21:37

May 28 (Reuters) - Prothena Corporation PLC  PRTA.O :
    * PROTHENA ANNOUNCES BRISTOL MYERS SQUIBB OPT-IN FOR
EXCLUSIVE
GLOBAL LICENSE FOR PRX019, THE SECOND PROGRAM FROM GLOBAL
NEUROSCIENCE RESEARCH AND DEVELOPMENT COLLABORATION
    * PROTHENA CORPORATION PLC - PROTHENA TO RECEIVE $80 MILLION
FROM
BRISTOL MYERS SQUIBB FOR EXCLUSIVE GLOBAL LICENSE TO PRX019
    * PROTHENA CORPORATION PLC - PROTHENA WILL INITIATE A PHASE
1
CLINICAL TRIAL FOR PRX019 IN 2024
    * PROTHENA CORPORATION PLC - BRISTOL MYERS SQUIBB OBTAINED
EXCLUSIVE GLOBAL LICENSE FOR PRX019 AND WILL PAY PROTHENA $80
MILLION
    * PROTHENA CORPORATION PLC - WILL BE ELIGIBLE TO RECEIVE
ADDITIONAL DEVELOPMENT, REGULATORY, AND SALES MILESTONE PAYMENTS
OF UP TO $617.5 MILLION
    * PROTHENA CORPORATION PLC - PROTHENA ALSO WILL BE ELIGIBLE
TO
RECEIVE TIERED ROYALTIES ON NET SALES

Source text for Eikon:  ID:nBw6slqMNa 
Further company coverage:  PRTA.O 

 ((Reutersbriefs@thomsonreuters.com;))